Verona Pharma has announced senior management changes with Dr. David Zaccardelli replacing Dr. Jan-Anders Karlsson as CEO, effective immediately, and Mark Hahn replacing Piers Morgan as CFO. In our view, the new US-based management, who join as a proven team, are solid appointments with strong CVs and a history of successfully working together. Most recently at Dova Pharmaceuticals until its $915m acquisition by Swedish Orphan Biovitrum (Sobi) in November 2019, and together have raised over $
03 Feb 2020
Senior management changes – new CEO and CFO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Senior management changes – new CEO and CFO
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
03 Feb 2020 -
Author:
Edward Thomason -
Pages:
4
Verona Pharma has announced senior management changes with Dr. David Zaccardelli replacing Dr. Jan-Anders Karlsson as CEO, effective immediately, and Mark Hahn replacing Piers Morgan as CFO. In our view, the new US-based management, who join as a proven team, are solid appointments with strong CVs and a history of successfully working together. Most recently at Dova Pharmaceuticals until its $915m acquisition by Swedish Orphan Biovitrum (Sobi) in November 2019, and together have raised over $